



Ifw

PATENT
ATTORNEY DOCKET NO. 47237-0561-00-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Yoshiyuki ISHIKURA et al.) Confirmation No.: 4059
Application No.: 10/541,073) Group Art Unit: 1615
Filed: June 29, 2005) Examiner: Unassigned
For: COMPOSITION HAVING ACTION PREVENTING OR ALLEVIATING SYMPTOMS OR
DISEASES DUE TO AGING OF BLOOD VESSELS

Commissioner for Patents
U.S. Patent and Trademark Office

Customer Window Mail Stop: ☐ New Application ☒ Amendment ☐ AF ☐ Issue Fee
Alexandria, VA 22314

Sir:

INFORMATION DISCLOSURE STATEMENT (IDS)

☒ **Under 37 C.F.R. § 1.97(b):** Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449. To the undersigned's knowledge, this IDS is being filed before the mailing date of a first Office Action on the merits, before the mailing date of a first Office Action on the merits after filing an RCE under § 1.114, or within three months of the application filing date.

☐ **Under 37 C.F.R. § 1.97(c):** Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449. This IDS is being filed after the events recited in § 1.97(b) but, to the undersigned's knowledge, before the mailing date of a Final Office Action, a Notice of Allowance, or another action that closes prosecution in the application.

☐ The fee of \$180.00 set forth in § 1.17(p) is included herein; or

☐ Applicant submits that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

☐ **Under 37 C.F.R. § 1.97(d):** Pursuant to 37 C.F.R. §§ 1.56 and 1.97(d), Applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449. This IDS is being filed after the events recited in § 1.97(c) but before payment of the issue fee.

☐ The fee of \$180.00 set forth in § 1.17(p) is included herein; and

☐ Applicant submits that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

☐ **Under 37 C.F.R. § 1.97(i):** Pursuant to 37 C.F.R. §§ 1.56 and 1.97(i), Applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449. This IDS is being filed after the events recited in § 1.97(d). Applicant requests that the IDS be placed in the file.

☒ A search report or other listing of documents from a counterpart, related, or other application dated January 18, 2005 and having documents cited thereon is attached for the Examiner's consideration. Any of these documents not previously cited, and any additional documents are listed on the PTO Form 1449.

☒ Applicant respectfully requests that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. As for any document listed on the accompanying PTO-1449 that is in a language other than English, relevance can be understood from an enclosed English abstract or at least partial translation or from mention in the specification or in a search report for a corresponding application.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that any of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicant reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should any of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this Application, including fees due under 37 C.F.R. § 1.16 and 1.17 which may be required and including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0573. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully submitted,

DRINKER, BIDDLE & REATH LLP



Ronald L. Grudziecki
Registration No. 24,970

Dated: July 11, 2006

CUSTOMER NO. 055694
DRINKER, BIDDLE & REATH LLP
1500 K Street, N.W., Suite 1100
Washington, D.C. 20005-1209
Tel: 202.842.8800; Fax: 202.842.8465



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Attorney Docket No.: 47237-0561-00-US	Serial No.: 10/541,073
	Applicants Yoshiyuki ISHIKURA et al.	Page 1 of 1
PTO Form 1449	Filing Date: June 29, 2005	Group Art Unit: 1615

U.S. PATENT DOCUMENTS

*Examiner Initial	Document Number	Date	Name	Class	Sub Class	Filing Date
	2004/0219208	11/04/2004	Kawamura et al.			
	2004/0266874	12/30/2004	Akimoto et al.			

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub Class	Translation YES NO
WO 01/03696	01/18/2001	PCT			
2001-31586	02/06/2001	Japan			Abstract
WO 02/102394	12/27/2002	PCT			
2003-504333	02/04/2003	Japan			Abstract
2003-048831	02/21/2003	Japan			Abstract
2003-113120	04/18/2003	Japan			Abstract

OTHER DOCUMENTS

(Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published)

	Mackay et al., "Arachidonic acid protects neonatal rat cardiac myocytes from ischaemic injury through ϵ protein kinase C," Cardiovascular Research, 2001, 50, pages 65-74.
	Horrobin, "Abnormal Membrane Concentrations of 20 and 22-Carbon Essential Fatty Acids: A Common Link Between Risk Factors and Coronary and Peripheral Vascular Disease?" Prostaglandins Leukotrienes and Essential Fatty Acids, 1995, 53, pages 385-396.

Examiner	Date Considered
----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.